Rapid Novor is the world leader in antibody protein sequencing technology and is home to the largest privately funded mass spectrometry proteomics facility in Canada. The team has over 20 years of experience specializing in proteomics, bioinformatics and Big Data processing and was the first to offer a commercial solution to distinguish between isoleucine and leucine (WILD®). Rapid Novor’s industry-leading REmAb® platform directly sequences antibody proteins, without needing access to the cell line.
[To receive an example of our report] - Email info@rapidnovor.com
